Invictus RG’s Novo Nordisk NVO Stock Holding History

Invictus RG’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-362	Closed	-$11K	–	668
2015 Q4	$11K	Buy	+362	New	+$10K	0.01%	512

Other funds holding NVO

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Invictus RG's NVO Position: Q1 2016 in Review

Invictus RG sold out of Novo Nordisk (NVO) in Q1 2016, closing a stake of 362 shares — an estimated $11K sold.

Invictus RG first reported a position in NVO in Q4 2015 and held it in 1 quarter. The position peaked at $11K in Q4 2015. 535 funds tracked by Wall St. Rank hold NVO as of Q1 2016.

Invictus RG reported no remaining Novo Nordisk position as of Q1 2016 after selling out during the quarter.
Invictus RG sold 362 Novo Nordisk shares in Q1 2016, an estimated $11K.
Invictus RG first reported a position in Novo Nordisk in Q4 2015 and held it in 1 quarter.
Invictus RG's Novo Nordisk position peaked at $11K in Q4 2015.
535 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2016.

Based on Invictus RG's 13F filing for Q1 2016, filed 16 May 2016.